Valion Bio posts Q1 net loss of $6.2M; cash falls to $7.2M; advances Entolimod

Valion Bio, Inc.

Net loss $6.2M ($2.23/share) vs $1.5M ($2.52/share) a year ago; operating expenses $5.6M (was $1.4M).
Cash and equivalents $7.2M at March 31, 2026, down from $12.6M at Dec 31, 2025.
Government engagement broadened with BARDA, NIAID, and Dept of War for Entolimod as ARS countermeasure.
Velocity Bioworks CDMO integration advancing; facility supports internal and third-party biologics manufacturing.
Pipeline includes Entolimod (Animal Rule pathway) and Entolasta (TLR5 agonist for oncology supportive care).

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.